The distribution, concentration, and toxicity of enhanced green fluorescent protein in retinal cells after genomic or somatic (virus-mediated) gene transfer.
Tonia S. Rex(Vanderbilt University Medical Center), Jean Bennett(Penn Presbyterian Medical Center), Arkady Lyubarsky(Penn Presbyterian Medical Center), Elisabeth Bendo(California University of Pennsylvania), Edward N. Pugh(Membrane Technology & Research (United States)), Enrico Maria Surace(Telethon Institute Of Genetics And Medicine), Thomas E. Hughes(Montana State University), Peter D. Calvert(Duke University), John A. Peet(California University of Pennsylvania), Sergei Nikonov(Penn Presbyterian Medical Center)
PubMed
December 30, 2005
Cited by 14
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate
|Nature Genetics|2000|506
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
|Science Translational Medicine|2012|394